#Sweden #Stockholm #Nevisense #SciBase #melanoma

Nevisense Recognized in NCCN Guidelines for Melanoma Detection

SciBase Holding AB, a prominent player in the dermatological technology landscape, has achieved a notable milestone as its flagship product, Nevisense (EIS), has been incorporated into the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for melanoma detection. This inclusion underscores the increasing importance of advanced diagnostic technologies in the fight against skin cancer, particularly melanoma, which continues to rise in incidence worldwide.

The NCCN Guidelines serve as a critical reference for oncology practices, setting standards for patient care and clinical strategy. With the addition of Nevisense, clinicians are provided with a sophisticated tool that enhances their ability to detect melanoma at earlier stages—a vital factor in improving treatment outcomes.

Dr. Alexander Meves, a leading dermatologist and professor at the Mayo Clinic, emphasized the impact of this advancement in clinical diagnostics. He stated, "The inclusion of Nevisense as a diagnostic support technology reinforces the necessity for objective methods in identifying melanoma. These guidelines assist healthcare professionals in integrating innovative technologies into their existing frameworks aimed at early detection."

Dr. Darrell Rigel, a Clinical Professor of Dermatology at New York University and Past President of the American Academy of Dermatology, remarked on the benefits of combining Nevisense with traditional assessment techniques. He noted, "While visual assessments and dermoscopy have proven effective, our research indicates that incorporating Nevisense improves detection rates significantly. This methodological enhancement is essential as we aim to refine clinical judgment and decision-making in dermatological practice."

As the global incidence of melanoma continues to escalate, there is an urgent demand for technologies that facilitate prompt and accurate diagnosis. Pia Renaudin, CEO of SciBase, acknowledged this necessity, stating, "The NCCN guidelines highlight the critical role of non-invasive, point-of-care technologies like Nevisense in enabling clinicians to detect melanoma earlier, ultimately enhancing outcomes for patients."

Nevisense operates on the principles of electrical impedance spectroscopy, an advanced diagnostic technology that leverages artificial intelligence to provide users with quantitative data about skin lesions. By offering clinicians a deeper understanding of suspicious lesions, Nevisense helps to inform clinical decisions that can lead to timely interventions and better patient management.

Built on over two decades of rigorous research at the Karolinska Institute in Stockholm, Sweden, SciBase has established itself as a leader in the dermatological technology arena. The company is dedicated to improving patient outcomes by minimizing suffering through early detection and reliable intervention strategies, simultaneously striving to reduce healthcare costs.

Since going public on the Nasdaq First North Growth Market in June 2015, SciBase continues to make strides in the dermatology sector. Interested parties can find more information about Nevisense and other initiatives by visiting SciBase’s official website.

In summary, the inclusion of Nevisense in the NCCN Guidelines marks a pivotal step forward in melanoma detection, encouraging the dermatology community to adopt innovative technologies that can lead to improved patient outcomes and streamlined care processes. This advancement reflects a collective commitment to fighting melanoma through enhanced diagnostic capabilities and better-informed clinical practices.